Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors (CgA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02759718|
Recruitment Status : Unknown
Verified April 2016 by Song Cheol Kim, Asan Medical Center.
Recruitment status was: Active, not recruiting
First Posted : May 3, 2016
Last Update Posted : May 3, 2016
Chromogranin A (CgA) is a glycoprotein with a molecular weight of 49 to 52 kDa produced by chromaffin cells of the adrenal medulla, enterochromaffin-like (ECL) cells, and endocrine cells of the stomach and pancreas, and it is the precursor to several functional peptides including vasostatin and pancreastatin.
Importantly, CgA can be measured in the serum or plasma or detected within the secretory vesicles as a general diagnostic biomarker for neuroendocrine tumors (NETs), and plasma CgA levels also provide information regarding tumor burden and response to treatment. It has a sensitivity and specificity between 27% and 81%.
Some studies have noted an association between CgA concentrations and tumor location or degree of differentiation. It has also been proposed that plasma CgA levels are more frequently elevated in well-differentiated tumors compared with poorly differentiated tumors of the midgut. Some other clinical series have provided evidence of an association between plasma CgA levels and the extent of disease, tumor burden, or presence of metastases, and high baseline levels of CgA are suggestive of a poor prognosis.
However, there exist still controversies the effectiveness of serum CgA levels on diagnostic relevance, treatment response after surgical resection or sandostatin analog, clinicopathologic features of pancreatic neuroendocrine tumors (PNETs).
To date, moreover, a precise association between CgA levels and survival has not been clearly demonstrated, although a number of studies suggest that this relationship may exist. There, especially, is no relevant data on value of serum CgA level for clinical usefulness in Korean population.
|Condition or disease||Intervention/treatment||Phase|
|Non Functioning Pancreatic Endocrine Tumor||Biological: Chromogranin A||Phase 4|
An interventional, prospective, multi center pilot study to assess the clinical relevance of CgA levels in patients with PNET as performed in current clinical practice.
There will be a measurement of CgA levels at baseline (preoperative measures after consent) and afterwards, in 3, 6, 12, and 24 months after resection. Immunoradiometric assay (IRMA, normal values: < 100 ng/mL) will be used.
The collection of blood samples will proceed as detailed below:
Extraction of samples for serum collection:
7 ml of blood without anticoagulants will be allowed to sit for 30 min at room temperature before the serum is separated by centrifugation (3500 rpm). The serum will be stored at -20ºC
Assessments: Baseline (preoperative measures after consent), 3,6, 12, and 24 months
Clinical parameters: weight, height, performance status, vital signs including blood pressure, clinical signs and symptoms, survival data
Blood biochemical parameters: Sodium, potassium, calcium, glucose, urea, creatinina, bilirubin, alkaline phosphatase, aspartate transaminase (AST), and alanine transaminase (ALT).
Computed tomography (CT) : preoperative condition, and 3,6,12,24 months after resection.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||111 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET)|
|Study Start Date :||June 2012|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||May 2017|
Experimental: pancreatic neuroendocrine tumor
Biological: Chromogranin A
The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
Other Name: CgA
- Diagnostic accuracy of th CgA in the patient with PNET, change from preoperative levels of CgA at 3 months [ Time Frame: preoperation, 3 months ]In the PNET group, the plasma level of CgA was regularly measured.
- Diagnostic accuracy of th CgA in the patient with disease progression, change from preoperative levels of CgA at 3, 6,12, and 24 months [ Time Frame: preoperation, 3 months, 6 months, 12months, 24 months ]In the PNET group, the plasma level of CgA was regularly checked to follow up the status of disease progression.
- Disease progression of PNET using CT imaging, change from preoperative imaging of CT at 3, 6,12, and 24 months [ Time Frame: preoperation, 3 months, 6 months, 12months, 24 months ]In the PNET group, the CT was regularly checked to follow up the status of disease progression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02759718
|Principal Investigator:||Songcheol Kim, MD PhD||Asan Medical Center|